IEZZI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 1.075
EU - Europa 682
AS - Asia 467
SA - Sud America 49
AF - Africa 4
Totale 2.277
Nazione #
US - Stati Uniti d'America 1.073
SG - Singapore 170
CN - Cina 160
IE - Irlanda 127
IT - Italia 110
SE - Svezia 103
DE - Germania 90
FR - Francia 76
UA - Ucraina 73
TR - Turchia 69
BR - Brasile 42
GB - Regno Unito 38
IN - India 23
VN - Vietnam 23
AT - Austria 14
RU - Federazione Russa 13
FI - Finlandia 12
HK - Hong Kong 11
CZ - Repubblica Ceca 10
RO - Romania 5
BE - Belgio 4
BD - Bangladesh 3
PY - Paraguay 3
UZ - Uzbekistan 3
KE - Kenya 2
PK - Pakistan 2
PL - Polonia 2
UY - Uruguay 2
BG - Bulgaria 1
BO - Bolivia 1
CA - Canada 1
CL - Cile 1
DK - Danimarca 1
IQ - Iraq 1
JO - Giordania 1
JP - Giappone 1
LT - Lituania 1
MA - Marocco 1
NL - Olanda 1
PT - Portogallo 1
TT - Trinidad e Tobago 1
ZA - Sudafrica 1
Totale 2.277
Città #
Chandler 238
Singapore 128
Jacksonville 127
Dublin 126
Dearborn 90
Ashburn 58
Houston 55
Princeton 52
Munich 43
Izmir 40
Nanjing 39
Wilmington 28
Altamura 26
Chieti 26
The Dalles 24
Beijing 23
Ann Arbor 21
Boardman 20
Dong Ket 20
Los Angeles 17
Southend 16
Cambridge 13
Kunming 13
Santa Clara 12
Hong Kong 11
New York 11
Nanchang 10
Washington 10
Brno 9
Pescara 9
Shenyang 9
Nuremberg 8
Jiaxing 7
Norwalk 7
Vienna 7
London 6
São Paulo 6
Tianjin 6
Chicago 5
Hebei 5
Helsinki 5
Brussels 4
Hefei 4
Tongling 4
Woodbridge 4
Zhengzhou 4
Dallas 3
Falls Church 3
Frankfurt am Main 3
Hangzhou 3
Perego 3
Pune 3
Savigliano 3
Tappahannock 3
Tashkent 3
Asunción 2
Campinas 2
Cerveteri 2
Changsha 2
Chennai 2
Joinville 2
Leicester 2
Loreto Aprutino 2
Montevideo 2
Moscow 2
Palagiano 2
Rio de Janeiro 2
Rome 2
San Francisco 2
Turku 2
Algonquin 1
Ameno 1
Amman 1
Amsterdam 1
Angra dos Reis 1
Ankara 1
Ansonia 1
Apo 1
Araçuaí 1
As Samawah 1
Ascoli Piceno 1
Barbacena 1
Belleville 1
Boston 1
Brdo 1
Brooklyn 1
Campobasso 1
Canary Wharf 1
Canton 1
Capivari 1
Castano Primo 1
Chaguanas 1
Changchun 1
Charlotte 1
Cirencester 1
Colleferro 1
Colomiers 1
Columbus 1
Copenhagen 1
Curitiba 1
Totale 1.493
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 124
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 119
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 115
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 107
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 105
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 103
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 101
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 101
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 99
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 98
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 94
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 94
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 91
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 89
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 88
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 87
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 87
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 86
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 82
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 81
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 78
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 77
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 77
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 75
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 72
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 64
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 40
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 35
Totale 2.469
Categoria #
all - tutte 9.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.866


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021139 20 1 31 2 7 30 3 4 5 5 3 28
2021/2022142 0 6 0 33 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024268 31 13 17 11 19 99 38 5 6 10 3 16
2024/2025458 30 67 63 27 10 42 17 24 48 36 46 48
2025/202655 55 0 0 0 0 0 0 0 0 0 0 0
Totale 2.469